Sisafe Nano-Silicon Drug Delivery Platform Is Ready For Commercialization After Years Of Research And Development And Significant Capital Investment

Nano-Silicon Drug Delivery Platform


Advances in research have enabled controlled and sustained release of drugs, allowing for lower dosages and long-term effects of the drug. Furthermore, new technologies such as nanotechnology and antibody-drug conjugates are being developed to reduce costs while increasing bioavailability. Safe and effective drug delivery is a significant challenge for pharmaceutical and biotechnology companies. To address drug delivery challenges in various conditions, companies formulate their drugs in a variety of dosage forms such as capsules, powders, inhalers, liquid, drops, tablets, transdermal patches, depot injection, and gels. 

Companies looking for better ways to improve the quality of their existing drugs can use this technology. In addition, with the nano-silicon drug delivery platform, new drugs used to treat chronic diseases can be delivered at low doses to the target sites. SiSafe will be extremely useful to pharmaceutical, animal health, biotech, and cosmeceutical companies in formulating and packaging drugs that would otherwise be difficult to formulate.

This new nanotechnology-based drug delivery platform provides competitive advantages such as improved safety, efficacy, controlled release, and drug release at the desired time. SiSafe Nano-Silicon Drug Delivery Platform is ready for commercialization after years of research and development and significant capital investment. SiSaf is looking for drug developers who want to improve their formulation with controlled release and lower doses. In November 2016, SiSaf received a USD 4.9 million investment from Singapore's Vickers Venture Partners and Exen Capital. This collaboration is expected to greatly assist SiSaf in reaching new markets around the world.

Presbyopia's high prevalence is expected to drive market growth. Presbyopia affects more than 1.1 billion people worldwide, with one-third of those affected being over the age of 50. More than 90% of the patients in this pool are from developing countries. As a result, during the forecast period, developing countries are expected to have a high demand for myopia and presbyopia treatment. 

Comments

Popular posts from this blog

Air Purifier works as a Sanitizer in the air which helps in reducing pollutants, allergens, and toxins

Polyethylene Terephthalate Is A Non-Toxic Plastic, Mostly Used For Manufacturing Medical Devices

With the use of High-Frequency alternating current, Radiofrequency Ablation Device convert Electromagnetic Energy into Heat Energy